Warnex Launches Test for Influenza a H1N1 Virus Mutation Associated With Resistance to Tamiflu(R)

LAVAL, QUEBEC, Aug 27 (MARKET WIRE) --
Warnex Inc. (TSX: WNX) announced today that its Medical Laboratories
division has launched a test for the detection of a mutation of the
pandemic influenza A H1N1 virus, which is associated with resistance to
Tamiflu(R), a drug used for the treatment and prevention of the flu. The
test specifically detects the H275Y mutation of the neuraminidase gene,
which has been shown to cause resistance to Tamiflu.

"We have begun to see cases of Tamiflu resistance of the A H1N1 virus on
a global scale, and recently also here in Quebec," said Mark Busgang,
President and CEO of Warnex. "We are offering this test for the
identification of a Tamiflu-resistant strain in addition to our test for
the rapid detection of the H1N1 flu virus, demonstrating the commitment
of our Medical Laboratories division to serve as a reference laboratory
and make available such highly specialized medical tests to the Canadian
healthcare sector."

Influenza A H1N1 virus, also known as human swine flu, is a variant of
the influenza A virus which was first detected in people in April 2009
and has been declared a pandemic by the World Health Organization. The A
H1N1 flu virus spreads from person to person, probably in much the same
way as regular seasonal influenza viruses. The symptoms of this new flu
virus are similar to the symptoms of seasonal flu and include fever,
cough, sore throat, runny or stuffy nose, body aches, headache, chills
and fatigue. A significant number of people who have been infected with
this virus have also reported diarrhea and vomiting. Also, like seasonal
flu, this virus can cause severe illness and death.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting
public health by providing laboratory services to the pharmaceutical and
healthcare sectors. Warnex Analytical Services provides pharmaceutical
and biotechnology companies with a variety of quality control services,
including chemistry, chromatography, microbiology, method development and
validation, and stability studies. Warnex Bioanalytical Services
specializes in bioequivalence and bioavailability studies for clinical
trials. Warnex Medical Laboratories provides specialized testing for the
healthcare industry as well as pharmaceutical and central laboratory
services. Warnex PRO-DNA Services offers DNA identification tests for
paternity, maternity and other family relationships, as well as for
immigration and forensic testing purposes. Warnex has three facilities
located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to
financial resources, government regulations, laboratory facilities,
suppliers, employees, key customers and business partners, foreign
currency risk, credit risk, liquidity risk, volatility of share price,
and other important factors that could cause actual results to differ
materially from those anticipated in the forward-looking statements,
please refer to the heading Risks and Uncertainties in Warnex's most
recent Management's Discussion and Analysis, which can be found at
www.sedar.com. Consequently, actual results may differ materially from
the anticipated results expressed in these forward-looking statements.

Contacts:
Warnex Inc.
Mark J. Busgang
President & CEO
450-663-6724 x 310
mbusgang@warnex.ca

Warnex Inc.
Catherine Sartoros
Communications Specialist
450-663-6724 x 277
csartoros@warnex.ca

Copyright 2009, Market Wire, All rights reserved.

-0-